Innoviva (INVA) Non-Current Assets (2010 - 2026)
Innoviva's (INVA) quarterly Non-Current Assets came in at $1.1 billion in Q1 2026, up 58.24% YoY from $672.4 million in Q1 2025, and up 17.22% on a QoQ basis from $907.6 million in Q4 2025.
Innoviva (INVA) Non-Current Assets (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Non-Current Assets data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Non-Current Assets rose 58.24% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 billion (up 2.58% YoY) and the FY2025 annual result came in at $907.6 million, up 21.55% from the prior year.
- Non-Current Assets advanced to $1.1 billion in Q1 2026, from $907.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.1 billion in Q1 2026 to a low of $59.6 million in Q3 2022.
- A 5-year average of $557.1 million and a median of $737.3 million in 2022 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 5746.67% in 2022, down 90.27% in 2022.
- Tracing INVA's Non-Current Assets over 5 years: stood at $59.6 million in 2022, then rose by 27.73% to $76.2 million in 2023, then soared by 880.3% to $746.8 million in 2024, then advanced by 21.55% to $907.6 million in 2025, then increased by 17.22% to $1.1 billion in 2026.
- The last three Non-Current Assets figures came in at $1.1 billion (Q1 2026), $907.6 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 949.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 949.36 Mn |
| Mar 31, 2026 | 1.06 Bn |
| Dec 31, 2025 | 907.65 Mn |
| Sep 30, 2025 | 72.59 Mn |
| Jun 30, 2025 | 681.79 Mn |
| Mar 31, 2025 | 672.37 Mn |
| Dec 31, 2024 | 746.75 Mn |
| Sep 30, 2024 | 75.85 Mn |
| Jun 30, 2024 | 866.64 Mn |
| Mar 31, 2024 | 956.27 Mn |
| Dec 31, 2023 | 76.18 Mn |
| Sep 30, 2023 | 76.18 Mn |
| Jun 30, 2023 | 794.70 Mn |
| Mar 31, 2023 | 833.32 Mn |
| Dec 31, 2022 | 59.64 Mn |
| Sep 30, 2022 | 59.64 Mn |
| Jun 30, 2022 | 737.31 Mn |
| Mar 31, 2022 | 789.65 Mn |
| Dec 31, 2021 | 612.72 Mn |
| Sep 30, 2021 | 1.02 Mn |